GSK shareholders to vote on Novartis megadeal in December

Glaxo shareholders will soon have the chance to weigh in on an asset swap between GlaxoSmithKline ($GSK) and Novartis ($NVS) worth more than $20 billion. The British pharma giant has asked its investors to vote at a Dec. 18 meeting on the proposed deal, which will send GSK's oncology drugs to Switzerland and most of Novartis' flu business to Glaxo, as well as establish a consumer healthcare JV. "This is the most significant transaction for the company since the creation of GlaxoSmithKline in 2000," GSK chairman Christopher Gent wrote in a shareholder letter seen by ReutersNews | More

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.